Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota

Link to article at PubMed

Front Pharmacol. 2023 Jul 17;14:1217306. doi: 10.3389/fphar.2023.1217306. eCollection 2023.


Proton pump inhibitors (PPIs) are the most used acid-inhibitory drugs, with a wide range of applications in the treatment of various digestive diseases. However, recently, there has been a growing number of digestive complications linked to PPIs, and several studies have indicated that the intestinal flora play an important role in these complications. Therefore, developing a greater understanding of the role of the gut microbiota in PPI-related digestive diseases is essential. Here, we summarize the current research on the correlation between PPI-related digestive disorders and intestinal flora and establish the altered strains and possible pathogenic mechanisms of the different diseases. We aimed to provide a theoretical basis and reference for the future treatment and prevention of PPI-related digestive complications based on the regulation of the intestinal microbiota.

PMID:37529701 | PMC:PMC10387554 | DOI:10.3389/fphar.2023.1217306

Leave a Reply

Your email address will not be published. Required fields are marked *